Efficacy of the Levonorgestrel-Releasing Intrauterine System on XXXX -ET Outcomes in @entity3610 With @entity1869 .

@entity1 @entity4396 @entity3610 @entity1420 @entity2692 @entity53 @entity1478 @entity1869 @entity52
OBJECTIVE: This study investigated the @entity52 ( @entity52 ) outcome of @entity2692 -releasing intrauterine system (LNG-IUS) pretreatment for @entity1869 (EH) in @entity1 with @entity3610 ( @entity3610 ) undergoing @entity52 embryo transfer ( @entity52 -ET). METHODS: One hundred ninety @entity1 with @entity3610 and simple EH without cytologic atypia were allocated randomly to 2 independent arms, that is, the LNG-IUS group (90 @entity1 ) and the non-LNG-IUS group (100 @entity1 ). Four hundred fourteen @entity1 with @entity3610 without @entity1478 comprised the control group. Each @entity1 was reevaluated by transvaginal ultrasonography (TVS) and endometrial biopsy after 6 months. For each @entity1 , @entity52 outcome measures, such as number of recombinant follicle-stimulating hormone, endometrial thickness on @entity1 chorionic gonadotropin (HCG) day, hormone levels ( @entity1420 , luetinizing hormone, and serum @entity53 ) on HCG day, number of oocytes, fertilization rate, clinical pregnancy rate, and miscarriage rate were compared among the 3 groups. RESULTS: In general, the 3 groups did not differ with respect to the main clinical and biochemical data. After 6 months, @entity1 in LNG-IUS group had an EH resolution rate of 87.77%. In the non-LNG-IUS group, the resolution rate was 15.00%, and 3% of these @entity1 showed progression of EH. The clinical pregnancy rates in the non-LNG-IUS group were significantly lower (28.04%) than that in the LNG-IUS group (46.06%) and the control group (44.65%). The miscarriage rate was highest in the non-LNG-IUS group, but no significant difference in miscarriage rate existed among the 3 groups. CONCLUSION: The study illustrates that the LNG-IUS can be safely used for 6 months as a treatment for @entity1 with @entity3610 and simple EH. Additionally, use of the LNG-IUS can increase the clinical pregnancy rates and implantation rates of @entity1 with @entity3610 and simple EH who undergo @entity4396 agonist @entity52 -ET protocols.
